Validating plasminogen activator inhibitor-1 as a poor prognostic factor in sepsis

Area of Science:

• Biochemistry
• Critical Care Medicine
• Hematology

Background:

• Plasminogen activator inhibitor-1 (PAI-1) is a key regulator of fibrinolysis.
• Previous studies suggested a link between high PAI-1 levels (≥83 ng/mL) and adverse outcomes in sepsis, including disseminated intravascular coagulation (DIC), organ dysfunction, and mortality.

Purpose of the Study:

• To validate 83 ng/mL as a clinically useful cut-off value for PAI-1 levels in predicting poor prognosis in sepsis patients.
• To assess the association between high PAI-1 levels and specific clinical outcomes in sepsis.

Main Methods:

• Single-center retrospective study involving patients with sepsis.
• Patients were stratified into high (≥83 ng/mL) and low (<83 ng/mL) PAI-1 groups.
• Comparison of pre-DIC state, ICU-free days, RRT-free days, ventilator-free days, catecholamine-free days, and 28-day survival rates between groups.

Main Results:

• The high PAI-1 group (61 patients) showed a significantly higher incidence of a pre-DIC state within one week (P=0.009).
• High PAI-1 levels were associated with significantly fewer ICU-free days (P=0.01), RRT-free days (P=0.02), and catecholamine-free days (P=0.02).
• Kaplan-Meier analysis revealed a significantly lower 28-day survival rate in the high PAI-1 group (log-rank, P=0.03).

Conclusions:

• Sepsis patients with PAI-1 levels of ≥83 ng/mL face elevated risks of coagulopathy, organ failure, and mortality.
• The 83 ng/mL threshold for PAI-1 appears to be a valuable cut-off for prognostication in sepsis.
• PAI-1 level monitoring can aid in identifying high-risk sepsis patients requiring closer management.